New study highlights CAR T-cell therapy success for lymphoma when used as standard of care

(H. Lee Moffitt Cancer Center& Research Institute) Moffitt Cancer Center partnered with 16 academic cancer centers to analyze real world data of 274 patients treated commercially with Yescarta ® (axicabtagene ciloleucel), one of two CAR T products that is now standard of care for patients with diffuse large B cell lymphoma (DLBCL) who have not responded to two or more therapies. The researchers then compared those figures with results from the pivotal ZUMA-1 trial, which included 101 patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news